Brussels makes strongest statement yet that it wants the UK in EU research programmes after Brexit, but says there can be no half in, half out arrangement on trade and EU agencies
Interim accommodation offered by Amsterdam in its winning bid was “not acceptable” says EMA director, Guido Rasi. Now the agency faces a ‘double transfer’ out of London, increasing costs and delaying the return to normal operations
UK medicines regulator seeks to allay pharma industry concern, reiterating a previous promise it will be pragmatic in setting new UK drugs rules in event of no-deal Brexit
Agency bracing itself for a potential exodus, while pharma companies fear a bottleneck in new drug approvals. Meanwhile, the bill for the removal stands at €400M
Employees are lukewarm on new locations and a slow-down in work rate will mean less income. In the best case scenario Europe’s drugs regulator will take 2-3 years to get back to speed after leaving London.
Only 5 of 19 cities bidding to host the European Medicines Agency would attract enough current employees for operations to continue as normal. Moving to one of the 8 least popular cities risks permanent damage, the agency warns
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.